Effect of Apatinib Combined with Carrelizumab on Advanced TNBC Patients and its Influence on Immune Function and Long-term Prognosis
Objective:To investigate the effect of apatinib combined with carrelizumab in the treatment of patients with advanced triple negative breast cancer(TNBC)and its effect on cellular immunity and long-term prognosis.Methods:A total of 82 patients with advanced TNBC admitted to our hospital from June 2019 to February 2022 were divided into two groups by random number table method,with 41 cases in each group.The single group was treated with carrelizumab,and the combined group was treated with apatinib.The clinical efficacy,cellular immune function,long-term prognosis and incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the combined group was higher than that of the single group(P<0.05).CD3+,CD4+ and NK cells in the two groups were higher than those before treatment,CD8+ was lower than that before treatment,and the change in the combined group was greater than that in the single group(P<0.05).There was no significant difference in total survival time and incidence of adverse reactions between the two groups(P>0.05).Conclusion:Apatinib combined with carrelizumab is effective in the treatment of advanced TNBC patients,which can significantly improve the cellular immune function,inhibit tumor progression,improve long-term prognosis,and does not increase the incidence of adverse reactions.It is safe and controllable.
ApatinibCarrelizumabTriple negative breast cancerCellular immune function
NETL
NSTL
万方数据
